全文获取类型
收费全文 | 1144篇 |
免费 | 76篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 7篇 |
妇产科学 | 17篇 |
基础医学 | 129篇 |
口腔科学 | 6篇 |
临床医学 | 123篇 |
内科学 | 320篇 |
皮肤病学 | 7篇 |
神经病学 | 138篇 |
特种医学 | 22篇 |
外科学 | 115篇 |
综合类 | 6篇 |
预防医学 | 60篇 |
眼科学 | 13篇 |
药学 | 162篇 |
中国医学 | 2篇 |
肿瘤学 | 90篇 |
出版年
2023年 | 16篇 |
2022年 | 22篇 |
2021年 | 43篇 |
2020年 | 33篇 |
2019年 | 34篇 |
2018年 | 36篇 |
2017年 | 33篇 |
2016年 | 27篇 |
2015年 | 39篇 |
2014年 | 34篇 |
2013年 | 51篇 |
2012年 | 72篇 |
2011年 | 96篇 |
2010年 | 35篇 |
2009年 | 27篇 |
2008年 | 45篇 |
2007年 | 59篇 |
2006年 | 37篇 |
2005年 | 37篇 |
2004年 | 37篇 |
2003年 | 23篇 |
2002年 | 24篇 |
2001年 | 15篇 |
2000年 | 18篇 |
1999年 | 9篇 |
1998年 | 7篇 |
1997年 | 8篇 |
1996年 | 8篇 |
1994年 | 8篇 |
1993年 | 9篇 |
1992年 | 24篇 |
1991年 | 21篇 |
1990年 | 22篇 |
1989年 | 14篇 |
1988年 | 14篇 |
1987年 | 6篇 |
1986年 | 15篇 |
1985年 | 22篇 |
1984年 | 15篇 |
1983年 | 11篇 |
1982年 | 14篇 |
1981年 | 7篇 |
1979年 | 11篇 |
1978年 | 6篇 |
1977年 | 10篇 |
1975年 | 5篇 |
1974年 | 5篇 |
1973年 | 5篇 |
1972年 | 6篇 |
1971年 | 6篇 |
排序方式: 共有1224条查询结果,搜索用时 15 毫秒
1.
Drug related hospital admissions 总被引:13,自引:0,他引:13
J. Hallas B. Harvald J. Worm J. Beck-Nielsen L. F. Gram E. Grodum N. Damsbo J. Schou H. Kromann-Andersen F. Frølund 《European journal of clinical pharmacology》1993,45(3):199-203
Summary As part of a high-intensity monitoring study of drug events as the cause of admission to departments of internal medicine, the effect of an educational intervention programme was studied. Two departments were included, one specialising in geriatrics and one that received patients by non-selected referral. The series consisted of 607 consecutive admissions studied before and 703 after the intervention. The drug events considered were adverse drug reactions and dose-related therapeutic failures, mainly due to non-compliance.A modest, statistically non-significant decrease in drug related hospital admissions (DRH) was seen, from 14% before to 13% after the intervention period. However, DRHs classified as definitely avoidable showed the significant decrease of 83%.There was no apparent relationship between the topics selected for the intervention programme and changes in the pattern of DRHs. No relationship between alterations in sales data and hospital admissions caused by a given drug could be demonstrated. A blinded external evaluation of case abstracts did not disclose any significant shift in the investigators' assessments.The intervention may have had an non-specific effect on avoidable DRHs. 相似文献
2.
K. Brøsen L. F. Gram P. N. Nielsen K. Brusgaard K. Skjødt 《European journal of clinical pharmacology》1994,47(3):221-225
CYP2D6 genotyping was carried out by XbaI restriction fragment length polymorphism analysis and polymerase chain reaction in 168 healthy Danish volunteers, 77 extensive metabolizers (EM) and 91 poor metabolizers (PM) of sparteine. All EM were genotyped correctly as heterozygous or homozygous for the functional (wild type) gene, D6-wt. However, the D6-wt gene was apparently also present in 11 (12%) of the PM who accordingly were incorrectly genotyped as EM. The specificity of genotyping PM thus was 100% but the sensitivity was only 88%. The most common allele was the D6-wt with an apparent frequency of 0.741 (0.026) in the Danish population and the second most common allele was the D6-B with an apparent frequency of 0.194 (0.024). The median (range) of the sparteine metabolic ratio (MR) in 47 homozygous D6-wt EM was 0.28 (0.11–4.10) and the corresponding value in heterozygous EM was 0.36 (0.11–9.10). The median difference was 0.09 (95% confidence interval: 0.02–0.16). CYP2D6 phenotyping is a promising tool in tailoring the individual dose of tricyclic antidepressants, some neuroleplics and some antiarrhythmics. However if the genotype test could be improved with regard to both sensitivity in PM and the ability to predict CYP2D6 activity in EM then it would be of even greater clinical value in therapeutic drug monitoring. 相似文献
3.
S. H. Sindrup L. Arendt-Nielsen K. Brøsen P. Bjerring H. R. Angelo B. Eriksen L. F. Gram 《European journal of clinical pharmacology》1992,42(6):587-591
Summary We have studied the hypoalgesic effect of codeine (100 mg) after blocking the hepatic O-demethylation of codeine to morphine via the sparteine oxygenase (CYP2D6) by quinidine (200 mg). The study was performed in 16 extensive metabolizers of sparteine, using a double-blind, randomized, four-way, cross-over design. The treatments given at 3 h intervals during the four sessions were placebo/placebo, quinidine/placebo, placebo/codeine, and quinidine/codeine. We measured pin-prick pain and pain tolerance thresholds to high energy argon laser stimuli before and 1, 2, and 3 h after codeine or placebo.After codeine and placebo, the peak plasma concentration of morphine was 6–62 (median 18) nmol·.l–1. When quinidine pre-treatment was given, no morphine could be detected (<4 nmol·l–1) after codeine. The pin-prick pain thresholds were significantly increased after placebo/codeine, but not after quinidine/codeine compared with placebo/placebo. Both placebo/codeine and quinidine/codeine increased pain tolerance thresholds significantly. Quinidine/codeine and quinidine/placebo did not differ significantly for either pin-prick or tolerance pain thresholds.These results are compatible with local CYP2D6 mediated formation of morphine in the brain, not being blocked by quinidine. Alternatively, a hypoalgesic effect of quinidine might have confounded the results. 相似文献
4.
Steady state plasma concentrations of imipramine and desipramine were studied at three to nine different imipramine dose levels in 17 extensive metabolizers of sparteine and at two dose levels in two poor metabolizers of sparteine, all treated for diabetic neuropathy symptoms. The imipramine doses were changed stepwise from doses yielding plasma concentrations of imipramine plus desipramine below 150 nM, up to doses yielding therapeutic drug levels of at least 300-500 nM. The imipramine doses required to achieve therapeutic drug levels was 20 or 25 mg/day in the two poor metabolizers and 50-350 mg/day in the extensive metabolizers. In the extensive metabolizers, the concentration/dose ratio increased for imipramine and desipramine with increasing dose. Dose adjustments based on a simple linear prediction from drug levels at initial dose (50 or 75 mg imipramine/day) thus would result in 0-130% (median, 20%) overestimates, most pronounced in patients with initial low steady state levels. The nonlinear kinetics of imipramine thus may be a significant clinical problem in patients treated for diabetic neuropathy symptoms. 相似文献
5.
L B Jensen P Vestergaard A P Hermann J Gram P Eiken B Abrahamsen C Brot N Kolthoff O H S?rensen H Beck-Nielsen S Pors Nielsen P Charles L Mosekilde 《Journal of bone and mineral research》2003,18(2):333-342
The aim of this study was to study the influence of hormone replacement therapy (HRT) on weight changes, body composition, and bone mass in early postmenopausal women in a partly randomized comprehensive cohort study design. A total of 2016 women ages 45-58 years from 3 months to 2 years past last menstrual bleeding were included. One thousand were randomly assigned to HRT or no HRT in an open trial, whereas the others were allocated according to their preferences. All were followed for 5 years for body weight, bone mass, and body composition measurements. Body weight increased less over the 5 years in women randomized to HRT (1.94 +/- 4.86 kg) than in women randomized to no HRT (2.57 +/- 4.63, p = 0.046). A similar pattern was seen in the group receiving HRT or not by their own choice. The smaller weight gain in women on HRT was almost entirely caused by a lesser gain in fat. The main determinant of the weight gain was a decline in physical fitness. Women opting for HRT had a significantly lower body weight at inclusion than the other participants, but the results in the self-selected part of the study followed the pattern found in the randomized part. The change in fat mass was the strongest predictor of bone changes in untreated women, whereas the change in lean body mass was the strongest predictor when HRT was given. Body weight increases after the menopause. The gain in weight is related to a decrease in working capacity. HRT is associated with a smaller increase in fat mass after menopause. Fat gain protects against bone loss in untreated women but not in HRT-treated women. The data suggest that women's attitudes to HRT are more positive if they have low body weight, but there is no evidence that the conclusions in this study are skewed by selection bias. 相似文献
6.
G. J. Gram A. Hemming A. Bolmstedt B. Jansson S. Olofsson L. Åkerblom J. O. Nielsen J. E. S. Hansen 《Archives of virology》1994,139(3-4):253-261
Summary Glycosylation is necessary for HIV-1 gp120 to attain a functional conformation, and individual N-linked glycans of gp120 are important, but not essential, for replication of HIV-1 in cell culture. We have constructed a mutant HIV-1 infectious clone lacking a signal for N-linked glycosylation in the V1-loop of HIV-1 gp120. Lack of an N-linked glycan was verified by a mobility enhancement of mutant gp120 in SDS-gel electrophoresis. The mutated virus showed no differences in either gp120 content per infectious unit or infectivity, indicating that the N-linked glycan was neither essential nor affecting viral infectivity in cell culture. We found that the mutated virus lacking an N-linked glycan in the V1-loop of gp120 was more resistant to neutralization by monoclonal antibodies to the V3-loop and neutralization by soluble recombinant CD4 (sCD4). Both viruses were equally well neutralized by ConA and a conformation dependent human antibody IAM-2G12. This suggests that the N-linked glycan in the V1-loop modulates the three-dimensional conformation of gp120, without changing the overall functional integrity of the molecule. 相似文献
7.
8.
9.
We reviewed the clinical safety of tiagabine HCl (TGB), a selective CNS GABA uptake inhibitor, in nearly 3100 patients from 53 separate clinical trials. TGB was found to have no clinically important effect upon hepatic metabolic processes, serum concentrations of concomitant antiepileptic drugs (AEDs), laboratory values, or important interactions with any common non-AEDs. Adverse effects were usually mild and involved the nervous system. TGB is safe and well-tolerated as add-on therapy for the treatment of partial seizures. 相似文献
10.
Steady-state kinetics of imipramine in patients 总被引:1,自引:0,他引:1
Lars F. Gram Ib Søndergaard Johannes Christiansen Gorm Odden Petersen Per Bech Niels Reisby Ilse Ibsen Jørgen Ortmann Adam Nagy Sven J. Dencker Ove Jacobsen Ole Krautwald 《Psychopharmacology》1977,54(3):255-261
Steady-state plasma level kinetics were studied in 76 patients given imipramine (IP) 150 to 225 mg/day for 2–5 weeks. IP was given in three divided doses at 8.00 a.m., 1.00 p.m. and 5.00 p.m. Plasma concentrations of IP and its active metabolite desipramine (DMI) were determined by quantitative in situ thin-layer chromatography. The plasma levels of IP and DMI showed pronounced flucutations throughout the day with a ratio of about 2 between highest and lowest level. Patients with steady-state levels of IP and/or DMI below 50 g/l reached this within 1 week of treatment. Patients with higher steady-state levels reached steady-state concentrations within 2–3 weeks. There were some intraindividual fluctuations in plasma levels from week to week after steady state had been reached (coefficient of variation: 10–20%). Interindividually, the steady-state levels corrected to a dose of 3.5 mg/kg per day varied considerably: IP: 6–356 g/l, DMI: 24–659 g/l and IP+DMI: 58–809 g/l. The steady-state plasma levels showed a skew distribution that became normal by logarithmic transformation. The IP/DMI ratio ranged from 0.07 to 5.5 with a median value of 0.47. Compared to data from amitriptyline treated patients the IP/DMI ratios had significantly lower median value and larger variation than the corresponding plasma level ratios of amitriptyline/nortriptyline. Several statistically significant differences in steady-state levels between age groups were found. For IP: Women aged 30–39 had lower levels than women aged 20–29, 40–49, and 50–59, and men aged 50–59 and 60–65; men aged 30–39 had lower levels than men aged 60–65. For DMI: Women aged 30–39 had lower levels than women aged 50–59. 相似文献